» Articles » PMID: 35205744

Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act Between Stemness, EMT Features and DNA Damage Responses

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Feb 25
PMID 35205744
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating tumor cells (CTCs) traverse vessels to travel from the primary tumor to distant organs where they adhere, transmigrate, and seed metastases. To cope with these challenges, CTCs have reached maximal flexibility to change their differentiation status, morphology, migratory capacity, and their responses to genotoxic stress caused by metabolic changes, hormones, the inflammatory environment, or cytostatic treatment. A significant percentage of breast cancer cells are defective in homologous recombination repair and other mechanisms that protect the integrity of the replication fork. To prevent cell death caused by broken forks, alternative, mutagenic repair, and bypass pathways are engaged but these increase genomic instability. CTCs, arising from such breast tumors, are endowed with an even larger toolbox of escape mechanisms that can be switched on and off at different stages during their journey according to the stress stimulus. Accumulating evidence suggests that DNA damage responses, DNA repair, and replication are integral parts of a regulatory network orchestrating the plasticity of stemness features and transitions between epithelial and mesenchymal states in CTCs. This review summarizes the published information on these regulatory circuits of relevance for the design of biomarkers reflecting CTC functions in real-time to monitor therapeutic responses and detect evolving chemoresistance mechanisms.

Citing Articles

Lessons (to be) learned from liquid biopsies: assessment of circulating cells and cell-free DNA in cancer and pregnancy-acquired microchimerism.

Bergmann L, Afflerbach A, Yuan T, Pantel K, Smit D Semin Immunopathol. 2025; 47(1):14.

PMID: 39893314 PMC: 11787191. DOI: 10.1007/s00281-025-01042-z.


Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response.

Xu S, Zheng Y, Ye M, Shen T, Zhang D, Li Z BMC Cancer. 2024; 24(1):1064.

PMID: 39198775 PMC: 11351591. DOI: 10.1186/s12885-024-12843-0.


Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance.

Guo Y, Wu H, Wiesmuller L, Chen M Cell Death Dis. 2024; 15(6):412.

PMID: 38866752 PMC: 11169513. DOI: 10.1038/s41419-024-06783-7.


DNA-PKcs/AKT1 inhibits epithelial-mesenchymal transition during radiation-induced pulmonary fibrosis by inducing ubiquitination and degradation of Twist1.

Yan Z, Zhu J, Liu Y, Li Z, Liang X, Zhou S Clin Transl Med. 2024; 14(5):e1690.

PMID: 38760896 PMC: 11101672. DOI: 10.1002/ctm2.1690.


PSME2 offers value as a biomarker of M1 macrophage infiltration in pan-cancer and inhibits osteosarcoma malignant phenotypes.

Li R, Yan L, Jiu J, Liu H, Li D, Li X Int J Biol Sci. 2024; 20(4):1452-1470.

PMID: 38385075 PMC: 10878157. DOI: 10.7150/ijbs.90226.


References
1.
Fougner C, Bergholtz H, Norum J, Sorlie T . Re-definition of claudin-low as a breast cancer phenotype. Nat Commun. 2020; 11(1):1787. PMC: 7156396. DOI: 10.1038/s41467-020-15574-5. View

2.
Fleisch M, Maxwell C, Barcellos-Hoff M . The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocr Relat Cancer. 2006; 13(2):379-400. DOI: 10.1677/erc.1.01112. View

3.
Baluapuri A, Wolf E, Eilers M . Target gene-independent functions of MYC oncoproteins. Nat Rev Mol Cell Biol. 2020; 21(5):255-267. PMC: 7611238. DOI: 10.1038/s41580-020-0215-2. View

4.
Xu G, Chapman J, Brandsma I, Yuan J, Mistrik M, Bouwman P . REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015; 521(7553):541-544. PMC: 4671316. DOI: 10.1038/nature14328. View

5.
Bertrand P, Saintigny Y, Lopez B . p53's double life: transactivation-independent repression of homologous recombination. Trends Genet. 2004; 20(6):235-43. DOI: 10.1016/j.tig.2004.04.003. View